Gilead Sciences Gets Europe Marketing Authorization for Vemlidy

Gilead Sciences Gets Europe Marketing Authorization for Vemlidy

Gilead Sciences shares gained 1% in early pre-market trade Wednesday after the biopharmaceutical firm said the European Commission granted it marketing authorization for Vemlidy 25mg, a once-daily tablet for the treatment of chronic hepatitis B virus infection in adults and adolescents. Vemlidy was approved by the U.S. Food and Drug Administration on Nov. 10 for the treatment of chronic HBV infection in adults with compensated liver disease, and by the […]

Read More ˃
MSC Industrial Fiscal Q1 Results Top Street Estimates

MSC Industrial Fiscal Q1 Results Top Street Estimates

MSC Industrial Direct Company, a provider of transportation services, reported Wednesday fiscal Q1 net income of $0.95 per share, up from $0.89 per share in the prior year period and higher than the $0.93 per share Street consensus provided by Capital IQ. Net sales for the quarter ended Dec. 3 were $686.3 million, down from $706.8 million reported for the same period last year, but still came in higher than […]

Read More ˃
Eli Lilly Expands Cancer Collaboration with Merck

Eli Lilly Expands Cancer Collaboration with Merck

Eli Lilly said pre-market Wednesday it has expanded an existing immuno-oncology collaboration with Merck to include a new phase 1 study that combines Lilly’s Lartruvo (olaratumbab) with Merck’s Keytruda in patients with previously treated advanced or metastatic soft tissue sarcoma. Shares of MRK were up almost 2% while LLY was inactive in recent pre-market. Eli Lilly said it will act as the sponsor of the phase 1 study with enrollment […]

Read More ˃